Lung cancer diagnosis begins with clinical assessment rather than with one universal test. A clinician considers symptoms, duration and progression, smoking and occupational history, previous illnesses, family history, examination findings and other relevant exposures. A persistent cough, unexplained breathlessness, coughing blood, recurrent chest infections or unexplained weight loss may prompt investigation. The GP may listen to the chest and arrange a chest X-ray or other testing. If the clinical picture suggests possible cancer, the patient may receive an urgent referral for specialist assessment. An urgent cancer referral does not itself mean that cancer has been diagnosed; it indicates that further investigation is warranted.
A chest X-ray is commonly used as an initial imaging investigation because it can identify masses, collapse, fluid or other abnormalities, but it cannot reliably establish whether an abnormality is malignant. Computed tomography provides much more detailed cross-sectional imaging and can show the size, shape and location of a lesion, relationships with airways and blood vessels, enlarged lymph nodes and abnormalities elsewhere in the chest. CT therefore plays a central role in evaluating a suspected lung cancer. Imaging can indicate that cancer is likely, but definitive classification frequently requires examination of cells or tissue.
Tissue diagnosis is obtained through different procedures depending on the location and characteristics of the suspected tumour. Bronchoscopy allows a specialist to pass a flexible instrument into the airways to inspect them and obtain samples. A needle biopsy may be performed through the chest wall under imaging guidance when a lesion is more accessible from outside the lung. Other techniques can sample lymph nodes or fluid surrounding the lung. The choice of procedure balances diagnostic yield, anatomical accessibility, risks such as bleeding or pneumothorax, and the information needed for treatment planning.
Pathologists examine biopsy or cytology specimens to determine whether malignant cells are present and, if so, what type of cancer they represent. Histology distinguishes major categories such as NSCLC and SCLC and can identify specific NSCLC subtypes, including adenocarcinoma and squamous cell carcinoma. This classification is clinically important because different tumour types can behave differently and respond differently to treatment. A diagnosis therefore involves more than identifying a mass on an imaging scan; it normally requires integrating radiological and pathological evidence.
Modern lung-cancer diagnosis may also involve molecular and biomarker testing, particularly for advanced NSCLC. Tumour cells can contain alterations in genes or signalling pathways that influence growth. Examples of clinically important molecular findings include alterations involving EGFR, ALK, ROS1, BRAF, KRAS and other pathways, while expression of proteins such as PD-L1 can help inform some immunotherapy decisions. Molecular testing does not replace histological diagnosis; it adds information about the biological characteristics of the cancer. The precise panel used depends on tumour type, stage, available tissue and contemporary clinical guidelines.
Once cancer has been established, doctors determine its stage. Staging asks how large or locally extensive the tumour is, whether regional lymph nodes contain cancer and whether distant metastases are present. NSCLC commonly uses the TNM system, assessing tumour extent, nodes and metastasis, whereas SCLC has traditionally been described using limited-stage and extensive-stage categories, although detailed staging systems can also be applied. Further imaging such as PET-CT, brain imaging or other scans may be used according to the clinical situation to determine the extent of disease.
Screening is different from diagnostic investigation. Screening is offered to selected people who have an elevated risk but do not necessarily have symptoms, with the objective of detecting cancer earlier. In England, targeted lung-health checks are being rolled out for eligible groups, and the NHS describes current programmes involving people aged 55 to 74 who have ever smoked, although availability varies by area and eligibility criteria apply. People with symptoms should not wait for screening; symptomatic individuals require diagnostic assessment.
No single investigation answers every diagnostic question. X-rays and CT scans provide anatomical information, biopsies provide cellular information, molecular tests provide biological information and staging investigations establish the extent of disease. Clinicians combine these findings with the patient's health and circumstances before deciding on treatment. If a biopsy is technically difficult or unsafe, doctors may sometimes use a combination of imaging, clinical evidence and other investigations, but treatment decisions depend on obtaining sufficient diagnostic certainty whenever possible. The diagnostic pathway is therefore a sequence of complementary investigations rather than a single test that simply labels a lung abnormality as cancer or non-cancer.
